Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)

Authors

E L Mayer, Dana-Farber Cancer Institute
K Clifton, Washington University School of Medicine in St. Louis
et al.

Journal

Annals of Oncology

Publication Date

2-1-2026

Volume

37

Issue

2

First Page

271

Last Page

277

Document Type

Open Access Publication

DOI

10.1016/j.annonc.2025.10.003

Rights and Permissions

Mayer EL, Hlauschek D, Gnant M, O'Brien PJ, Bellet-Ezquerra M, Goetz MP, Ruiz-Borrego M, Chan A, Clifton K, Egle D, Lake D, Cabrera P, Mamounas T, Pristauz-Telsnigg G, Dayao Z, Gil Gil M, Cameron D, Traina T, Morris PG, Sabanathan D, Rinnerthaler G, Meisel J, Prat A, Wolff AC, Tseng LM, Isaacs C, Singer CF, Rubovszky G, Foukakis T, Jassem J, Winer EP, Vetter M, Federmann J, Metzger O, Schurmans C, Gauthier E, Lu DR, Fesl C, Dueck A, DeMichele A. Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13). Ann Oncol. 2026 Feb;37(2):271-277. doi: 10.1016/j.annonc.2025.10.003. © 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NCND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Mayer, E L; Clifton, K; and et al., "Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)." Annals of Oncology. 37, 2. 271 - 277. (2026).
https://digitalcommons.wustl.edu/oa_4/6438

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.